Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II–III clinical trials of major pharmaceutical companies: new structural trends …

Y Zhou, J Wang, Z Gu, S Wang, W Zhu… - Chemical …, 2016 - ACS Publications
Fluoroorganic chemistry has become essential in the evolution of many different but
interconnected research fields. These include the development of new materials with a …

hERG toxicity assessment: Useful guidelines for drug design

A Garrido, A Lepailleur, SM Mignani… - European journal of …, 2020 - Elsevier
All along the drug development process, one of the most frequent adverse side effects,
leading to the failure of drugs, is the cardiac arrhythmias. Such failure is mostly related to the …

SLC6 neurotransmitter transporters: structure, function, and regulation

AS Kristensen, J Andersen, TN Jørgensen… - Pharmacological …, 2011 - ASPET
The neurotransmitter transporters (NTTs) belonging to the solute carrier 6 (SLC6) gene
family (also referred to as the neurotransmitter-sodium-symporter family or Na+/Cl …

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

S Aringhieri, M Carli, S Kolachalam, V Verdesca… - Pharmacology & …, 2018 - Elsevier
The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug
clozapine has been a revolutionary pharmacological step for treating psychotic patients as …

Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia

M Carbon, CU Correll - CNS spectrums, 2014 - cambridge.org
Since currently available antipsychotic medications predominantly treat hallucinations,
delusions, disorganized thoughts and behavior, and related agitation/aggression, attention …

Structural insights into the inhibition of glycine reuptake

A Shahsavar, P Stohler, G Bourenkov, I Zimmermann… - Nature, 2021 - nature.com
The human glycine transporter 1 (GlyT1) regulates glycine-mediated neuronal excitation
and inhibition through the sodium-and chloride-dependent reuptake of glycine,–. Inhibition …

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia

DC Javitt, SR Zukin, U Heresco-Levy… - Schizophrenia …, 2012 - academic.oup.com
Over the last 20 years, glutamatergic models of schizophrenia have become increasingly
accepted as etiopathological models of schizophrenia, based on the observation that …

Amino acid transporters as targets for cancer therapy: why, where, when, and how

S Bröer - International journal of molecular sciences, 2020 - mdpi.com
Amino acids are indispensable for the growth of cancer cells. This includes essential amino
acids, the carbon skeleton of which cannot be synthesized, and conditionally essential …

Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain

RJ Harvey, BK Yee - Nature reviews Drug discovery, 2013 - nature.com
Glycine transporters are endogenous regulators of the dual functions of glycine, which acts
as a classical inhibitory neurotransmitter at glycinergic synapses and as a modulator of …

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

D Umbricht, D Alberati, M Martin-Facklam… - JAMA …, 2014 - jamanetwork.com
Importance In schizophrenia, the severity of negative symptoms is a key predictor of long-
term disability. Deficient signaling through theN-methyl-D-aspartate receptor is hypothesized …